ERBB2 and breast cancer: In triple-negative (TNBC) and HER2-positive BC, published pCR rates are highest and strongly predict improved survival, while pCR rates are substantially lower in luminal BC (ER-positive, HER2-negative) and have a less obvious prognostic value [2].